10-<4-(3-hydroxypropyl)piperazino>-8-methylsulfonyl-10,11-dihydrodibenzothiepin | 74667-71-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并硫平类
• 英文名称: 10-<4-(3-hydroxypropyl)piperazino>-8-methylsulfonyl-10,11-dihydrodibenzothiepin
• 英文别名: 3-[4-(3-Methylsulfonyl-5,6-dihydrobenzo[b][1]benzothiepin-5-yl)piperazin-1-yl]propan-1-ol
• CAS: 74667-71-3
• 化学式: C₂₂H₂₈N₂O₃S₂
• 分子量: 432.608
• InChiKey: OBNYDKZKNJJFKM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  29
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  94.5
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  10-<4-(3-hydroxypropyl)piperazino>-8-methylsulfonyl-10,11-dihydrodibenzothiepin 在 双氧水 作用下， 以 乙醇 为溶剂， 反应 48.0h， 以89%的产率得到3-[4-(8-甲基磺酰基-5,6-二氢苯并[b][1]苯并硫杂卓-6-基)-1-氧代哌嗪-1-鎓-1-基]丙-1-醇
  参考文献：
  名称：

  10-[4-(3-Hydroxypropyl)piperazino]-8-methylsulfonyl-10,11-dihydrodibenzo[b,f]thiepin and some related potential metabolites of the neuroleptic agents oxyprothepin and methiothepin

  摘要：

  10-氯-8-甲基磺酰基-10,11-二氢二苯并[b,f]噻吩与1-(3-羟基丙基)哌嗪发生了取代反应，生成了标题化合物IV，通过选择性氧化反应转化为亚氧化物X、N-氧化物XII和N,S-二氧化物XIII。次胺VII通过碳酸酯VI制备，氧化为亚氧化物XI。10-氯-8-甲基磺酰基-10,11-二氢二苯并[b,f]噻吩与乙二胺反应得到二胺XIV，氧化为相应的亚氧化物XV。化合物IV, VII和X-XV是神经阻滞剂奥西普罗替平(II)的潜在代谢产物；化合物VII, XI, XIV和XV是甲硫噻嘧啶(I)的潜在代谢产物。在制备的化合物中，仅标题化合物IV保留了神经阻滞特性。

  DOI：

  10.1135/cccc19800529
• 作为产物：
  描述：

  1-哌嗪基丙醇 、 10-chloro-8-methylsulfonyl-10,11-dihydrodibenzothiepin 以 氯仿 为溶剂， 反应 14.0h， 以12%的产率得到2-methylsulfonyldibenzothiepin
  参考文献：
  名称：

  10-[4-(3-Hydroxypropyl)piperazino]-8-methylsulfonyl-10,11-dihydrodibenzo[b,f]thiepin and some related potential metabolites of the neuroleptic agents oxyprothepin and methiothepin

  摘要：

  10-氯-8-甲基磺酰基-10,11-二氢二苯并[b,f]噻吩与1-(3-羟基丙基)哌嗪发生了取代反应，生成了标题化合物IV，通过选择性氧化反应转化为亚氧化物X、N-氧化物XII和N,S-二氧化物XIII。次胺VII通过碳酸酯VI制备，氧化为亚氧化物XI。10-氯-8-甲基磺酰基-10,11-二氢二苯并[b,f]噻吩与乙二胺反应得到二胺XIV，氧化为相应的亚氧化物XV。化合物IV, VII和X-XV是神经阻滞剂奥西普罗替平(II)的潜在代谢产物；化合物VII, XI, XIV和XV是甲硫噻嘧啶(I)的潜在代谢产物。在制备的化合物中，仅标题化合物IV保留了神经阻滞特性。

  DOI：

  10.1135/cccc19800529

文献信息

• LIGANDS THAT TARGET HEPATITIS C VIRUS E2 PROTEIN
  申请人：BALHORN Rodney

  公开号：US20160361311A1

  公开（公告）日：2016-12-15

  Hepatitis C Virus (HCV) infects 200 million individuals worldwide. Although several FDA approved drugs targeting the HCV serine protease and polymerase have shown promising results, there is a need for better drugs that are effective in treating a broader range of HCV genotypes and subtypes without being used in combination with interferon and/or ribavirin. Recently, the crystal structure of the core of the HCV E2 protein (E2c) has been determined, providing structural information that can now be used to target the E2 protein and develop drugs that disrupt the early stages of HCV infection by blocking E2's interaction with different host factors. By targeting sites containing conserved E2 amino acids in the CD81 binding site on HCV E2, one might also be able to develop drugs that block HCV infection in a genotype-independent manner. Using the E2c structure as a template, a structural model of the E2 protein core (residues 421-645) was developed that includes the three amino acid segments that are not present in the E2c crystal structure. Blind docking of a diverse library of 1715 small molecules to this model led to the identification of a set of 34 ligands predicted to bind near conserved amino acid residues involved in the HCV E2:CD81 interaction. Surface plasmon resonance was used to screen the ligand set for binding to recombinant E2 protein, and the best binders were subsequently tested to identify compounds that inhibit the infection of hepatocytes by HCV. One compound, 281816, blocked E2 binding to CD81 and inhibited hepatocyte infection by HCV genotypes 1a, 1b, 2a, 2b, 4a and 6a with IC50's ranging from 2.2 μM to 4.6 μM. Methods are described for preventing or treating HCV infection using small molecule inhibitors such as 281816 that target E2 and disrupt its interactions.
• 10-[4-(3-Hydroxypropyl)piperazino]-8-methylsulfonyl-10,11-dihydrodibenzo[b,f]thiepin and some related potential metabolites of the neuroleptic agents oxyprothepin and methiothepin
  作者：Vladimír Valenta、Antonín Dlabač、Marie Bartošová、Emil Svátek、Miroslav Protiva

  DOI：10.1135/cccc19800529

  日期：——

  Substitution reaction of 10-chloro-8-methylsulfonyl-10,11-dihydrodibenzo[b,f]thiepin with 1-(3-hydroxypropyl)piperazine afforded the title compound IV which was transformed by selective oxidation reactions to the sulfoxide X, N-oxide XII and N,S-dioxide XIII. The secondary amine VII was prepared via the carbamate VI and oxidized to the sulfoxide XI. Reaction of 10-chloro-8-methylsulfonyl-10,11-dihydrodibenzo[b,f]thiepin with ethylenediamine gave the diamine XIV which was oxidized to the corresponding sulfoxide XV. Compounds IV, VII and X-XV are potential metabolites of the neuroleptic agent oxyprothepin (II); compounds VII, XI, XIV and XV are potential metabolites of methiothepin (I). Out of the compounds prepared, only the title compound IV preserves the neuroleptic character.

  10-氯-8-甲基磺酰基-10,11-二氢二苯并[b,f]噻吩与1-(3-羟基丙基)哌嗪发生了取代反应，生成了标题化合物IV，通过选择性氧化反应转化为亚氧化物X、N-氧化物XII和N,S-二氧化物XIII。次胺VII通过碳酸酯VI制备，氧化为亚氧化物XI。10-氯-8-甲基磺酰基-10,11-二氢二苯并[b,f]噻吩与乙二胺反应得到二胺XIV，氧化为相应的亚氧化物XV。化合物IV, VII和X-XV是神经阻滞剂奥西普罗替平(II)的潜在代谢产物；化合物VII, XI, XIV和XV是甲硫噻嘧啶(I)的潜在代谢产物。在制备的化合物中，仅标题化合物IV保留了神经阻滞特性。